Beta-Blockers for Primary Therapy of Heart Failure With Preserved Ejection Fraction: An Idea Whose Time has Gone?

The beneficial effects of beta-blockers (BB) in heart failure (HF) with reduced ejection fraction (HFrEF), including large ( ∼60%) reductions in mortality even on top of other mortality-reducing agents, are well established. However, there is uncertainty regarding the potential benefits and risks of BB for patients with HF with preserved ejection fraction (HFpEF), with a considerable amount of data suggesting lack of be nefit or even worsening. In this issue of the Journal, Nambiar et al. provide additional valuable data regarding this important question.
Source: Journal of Cardiac Failure - Category: Cardiology Authors: Source Type: research